DAIICHI SANKYO COMPANY, LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35.38 USD | +2.61% |
|
+2.17% | +29.36% |
| 05-28 | RevolKa Signs Master Service Agreement with Daiichi Sankyo | CI |
| 05-27 | AstraZeneca, Daiichi Sankyo's Experimental Lung Cancer Drug Shows Improvement in Patients | DJ |
| Sales 2024 | 1,602B 10.18B 799B | Sales 2025 * | 1,772B 11.26B 884B | Capitalization | 10,693B 67.93B 5,334B |
|---|---|---|---|---|---|
| Net income 2024 | 201B 1.28B 100B | Net income 2025 * | 197B 1.25B 98.1B | EV / Sales 2024 | 5.38 x |
| Net cash position 2024 | 545B 3.47B 272B | Net cash position 2025 * | 684B 4.34B 341B | EV / Sales 2025 * | 5.65 x |
| P/E ratio 2024 |
45.6
x | P/E ratio 2025 * |
54.2
x | Employees | 17,435 |
| Yield 2024 |
1.05% | Yield 2025 * |
1.08% | Free-Float | 97.04% |
More Fundamentals
* Assessed data
More news
Latest transcript on Daiichi Sankyo Company, Limited
More recommendations
More press releases
More news
| 1 day | +2.61% | ||
| 1 week | +2.17% | ||
| Current month | -0.03% | ||
| 1 month | +6.02% | ||
| 3 months | +7.67% | ||
| 6 months | +30.51% | ||
| Current year | +29.36% |
1 week
34.18
35.54
1 month
32.9337.18
Current year
26.5037.18
1 year
23.7237.57
3 years
18.0537.57
5 years
16.1138.00
10 years
4.4538.00
| Managers | Title | Age | Since |
|---|---|---|---|
Sunao Manabe
CEO | Chief Executive Officer | 69 | 31/03/07 |
Hiroyuki Okuzawa
PSD | President | 61 | 31/03/17 |
Ken Takeshita
CTO | Chief Tech/Sci/R&D Officer | - | 31/03/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sawako Nohara
BRD | Director/Board Member | 66 | 31/05/19 |
Kazuaki Kama
BRD | Director/Board Member | 75 | 31/05/19 |
Sunao Manabe
CEO | Chief Executive Officer | 69 | 31/03/07 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/05/24 | 35.39 | +2.64% | 112,282 |
| 30/05/24 | 34.48 | +0.70% | 389,473 |
| 29/05/24 | 34.24 | -1.81% | 145,469 |
| 28/05/24 | 34.87 | +0.69% | 79,340 |
| 24/05/24 | 34.63 | +2.00% | 59,229 |
Delayed Quote OTC Markets, May 31, 2024 at 08:59 pm
More quotes
Daiichi Sankyo Company specializes in developing, manufacturing and marketing pharmaceutical products. Net sales break down by activity as follows:
- sale of medicines (99.8%): prescription medicines (92.8% of net sales) and OTC medicines (7.2%) primarily for the treatment of thrombotic disorders, tumors, diabetes and rheumatoid arthritis;
- other (0.2%): primarily real estate activities.
Net sales are distributed geographically as follows: Japan (64.1%), North America (17.2%), Europe (9.7%) and other (9%).
Sector
Pharmaceuticals
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
5,578
JPY
Average target price
5,977
JPY
Spread / Average Target
+7.15%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| +9.78% | 210B | |
| -5.52% | 206B | |
| +6.17% | 164B |
- Stock Market
- Equities
- 4568 Stock
- DSNKY Stock
